Madrigal Pharmaceuticals, Inc., was established in March 2000 and began operations in July 2001. The company is a biopharmaceutical company focused on providing new treatments for metabolic dysfunction-related steatohepatitis. Steatohepatitis is a serious liver disease with highly unmet medical needs that can lead to cirrhosis, liver failure, cancer, liver transplant needs and premature death. The company's drug, Rezifra, is a once-daily oral liver-directed thyroid hormone receptor beta agonist designed to target a key underlying cause of MASH. 

Expected P&L on Expiry

Key Stats

Pricing Model

About MDGL20260417C460